{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-023199","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-07-09T20:08:54+00:00","discovered_at":"2026-07-09T20:10:00.464306+00:00","generated_at":"2026-07-09T20:10:07.039540+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmuCell Q2 product sales rise 11.5% to $7.2M; domestic sales up 27.7% YoY","bullets":["Q2 2026 total product sales $7.2M vs $6.4M in Q2 2025, an 11.5% increase.","Domestic sales grew 27.7% to $6.2M; international sales fell 38.9% to $1.0M.","First-half 2026 product sales $17.5M, up 20.9% from $14.5M in H1 2025.","Tri-Shield sales up 8.3% to $4.9M; Dual-Force and other sales up 19.1% to $2.3M in Q2.","Results are preliminary and unaudited; full Q2 earnings call scheduled for Aug 14, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-023199","json":"https://secwatch.observer/filing/0001437749-26-023199.json","markdown":"https://secwatch.observer/filing/0001437749-26-023199.md","text":"https://secwatch.observer/filing/0001437749-26-023199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/0001437749-26-023199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/iccc20260708_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T20:10:07.039540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}